Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis

Chih Wei Luan; Liang Tseng Kuo; Yun Ting Wang; Chun Ta Liao; Chung Jan Kang; Yi Chan Lee; Kuan Yin Chen; Chia Hsuan Lai; Yuan Hsiung Tsai; Ethan I. Huang; Ming Shao Tsai; Cheng Ming Hsu; Geng He Chang; Yao Te Tsai

doi:10.1002/hed.27397

Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis

Chih Wei Luan, Liang Tseng Kuo, Yun Ting Wang, Chun Ta Liao, Chung Jan Kang, Yi Chan Lee, Kuan Yin Chen, Chia Hsuan Lai, Yuan Hsiung Tsai, Ethan I. Huang, Ming Shao Tsai, Cheng Ming Hsu, Geng He Chang, Yao Te Tsai^*

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69–3.38), overall survival (HR = 2.40, 95% CI 1.94–2.98), disease-specific survival (HR = 2.57, 95% CI 1.71–3.88), and disease-free survival (HR = 2.67, 95% CI 1.51–4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.

Original language	English
Pages (from-to)	1856-1867
Number of pages	12
Journal	Head and Neck
Volume	45
Issue number	7
DOIs	https://doi.org/10.1002/hed.27397
State	Published - 07 2023

Bibliographical note

Keywords

head and neck cancer
meta-analysis
modified Glasgow prognostic score
squamous cell carcinoma
survival outcome
Disease-Free Survival
Squamous Cell Carcinoma of Head and Neck
Prognosis
Humans
Proportional Hazards Models
Head and Neck Neoplasms/therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.27397

Cite this

Luan, C. W., Kuo, L. T., Wang, Y. T., Liao, C. T., Kang, C. J., Lee, Y. C., Chen, K. Y., Lai, C. H., Tsai, Y. H., Huang, E. I., Tsai, M. S., Hsu, C. M., Chang, G. H., & Tsai, Y. T. (2023). Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis. Head and Neck, 45(7), 1856-1867. https://doi.org/10.1002/hed.27397

@article{733ecc64b3c347c7b75b70b8fda25762,

title = "Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis",

abstract = "Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69–3.38), overall survival (HR = 2.40, 95% CI 1.94–2.98), disease-specific survival (HR = 2.57, 95% CI 1.71–3.88), and disease-free survival (HR = 2.67, 95% CI 1.51–4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.",

keywords = "head and neck cancer, meta-analysis, modified Glasgow prognostic score, squamous cell carcinoma, survival outcome, Disease-Free Survival, Squamous Cell Carcinoma of Head and Neck, Prognosis, Humans, Proportional Hazards Models, Head and Neck Neoplasms/therapy",

author = "Luan, {Chih Wei} and Kuo, {Liang Tseng} and Wang, {Yun Ting} and Liao, {Chun Ta} and Kang, {Chung Jan} and Lee, {Yi Chan} and Chen, {Kuan Yin} and Lai, {Chia Hsuan} and Tsai, {Yuan Hsiung} and Huang, {Ethan I.} and Tsai, {Ming Shao} and Hsu, {Cheng Ming} and Chang, {Geng He} and Tsai, {Yao Te}",

note = "{\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2023",

month = jul,

doi = "10.1002/hed.27397",

language = "英语",

volume = "45",

pages = "1856--1867",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma

T2 - Systematic review and meta-analysis

AU - Luan, Chih Wei

AU - Kuo, Liang Tseng

AU - Wang, Yun Ting

AU - Liao, Chun Ta

AU - Kang, Chung Jan

AU - Lee, Yi Chan

AU - Chen, Kuan Yin

AU - Lai, Chia Hsuan

AU - Tsai, Yuan Hsiung

AU - Huang, Ethan I.

AU - Tsai, Ming Shao

AU - Hsu, Cheng Ming

AU - Chang, Geng He

AU - Tsai, Yao Te

PY - 2023/7

Y1 - 2023/7

N2 - Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69–3.38), overall survival (HR = 2.40, 95% CI 1.94–2.98), disease-specific survival (HR = 2.57, 95% CI 1.71–3.88), and disease-free survival (HR = 2.67, 95% CI 1.51–4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.

AB - Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69–3.38), overall survival (HR = 2.40, 95% CI 1.94–2.98), disease-specific survival (HR = 2.57, 95% CI 1.71–3.88), and disease-free survival (HR = 2.67, 95% CI 1.51–4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.

KW - head and neck cancer

KW - meta-analysis

KW - modified Glasgow prognostic score

KW - squamous cell carcinoma

KW - survival outcome

KW - Disease-Free Survival

KW - Squamous Cell Carcinoma of Head and Neck

KW - Prognosis

KW - Humans

KW - Proportional Hazards Models

KW - Head and Neck Neoplasms/therapy

UR - http://www.scopus.com/inward/record.url?scp=85159077656&partnerID=8YFLogxK

U2 - 10.1002/hed.27397

DO - 10.1002/hed.27397

M3 - 文献综述

C2 - 37161915

AN - SCOPUS:85159077656

SN - 1043-3074

VL - 45

SP - 1856

EP - 1867

JO - Head and Neck

JF - Head and Neck

IS - 7

ER -

Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this